The Mylan telmisartan amlodipine recall is back in the headlines, but it is not new. The recall of telmisartan 40 mg and amlodipine 5 mg combination tablets was initiated on 1 October 2026, the FDA classified it as Class III on 16 October, and press coverage in the following weeks has brought it to a wider audience. Reports say the tablets may be superpotent, meaning the telmisartan content in some lots may exceed the specification. This article sets out the affected lots, the meaning of Class III, what patients are generally advised to do and what we could and could not verify.
Key takeaways from the Mylan telmisartan amlodipine recall
- The recall covers 21,620 bottles of 30-count telmisartan 40 mg and amlodipine 5 mg tablets, according to reports of the FDA enforcement record.
- Five lots are named: 3228113, 3228114 and 3228115 (expiry 31 October 2026) and 3228120 and 3228121 (expiry 30 November 2026).
- The reason given is that the telmisartan content may exceed the established potency specifications.
- It is a Class III recall, which the FDA uses where a product is not likely to cause adverse health consequences.
- The recall began on 1 October 2026; the recalling firm is listed as Viatris, with the product made in India for Mylan Pharmaceuticals.
Which lots are in the Mylan telmisartan amlodipine recall
Two independent press accounts of the FDA enforcement entry give the same details. The product is a prescription generic combination tablet in 30-count bottles, distributed nationwide in the United States. One report cites the NDC 0378-1075-93. The first three lots expire on 31 October 2026 and the last two on 30 November 2026. Patients can usually find the lot number and expiry date on the bottle label, and a pharmacist can help check it. We could not load the live FDA enforcement record when preparing this article, so the lot details rest on the two reports and should be confirmed on the FDA’s Enforcement Report.
Is it Mylan or Viatris in the Mylan telmisartan amlodipine recall
Press coverage uses both names, which can confuse readers. The reports list Viatris as the recalling firm and say the tablets were made in India for Mylan Pharmaceuticals, based in Morgantown, West Virginia. Mylan is part of Viatris, which was formed from the combination of Mylan and a division of Pfizer, so the two names refer to the same corporate family. We have not seen a statement from the company, and the reports say none was issued.
What Class III means in the Mylan telmisartan amlodipine recall
The FDA sorts recalls into three classes by risk. Class I is for products that could cause serious harm or death, Class II for products that might cause temporary or reversible harm, and Class III for situations where use is not likely to cause adverse health consequences. This recall is Class III, the lowest tier, and the FDA assigned it on 16 October 2026. The reports say the FDA did not state how much telmisartan the affected tablets may contain, so we cannot say how far above specification any lot was. Background on recalls is at the FDA drug recalls page.
What patients taking telmisartan and amlodipine are generally advised to do
Press reports say neither the companies nor the FDA gave specific instructions in this case, and that the FDA’s general guidance is that patients can usually keep taking a medicine in a Class II or III recall unless told otherwise, because stopping a blood-pressure drug can itself be harmful. Anyone taking this combination should talk to their doctor or pharmacist, check the lot number and not stop or change their medicine on their own. This article is general information and not medical advice.
Why potency matters in the Mylan telmisartan amlodipine recall
Telmisartan is an angiotensin receptor blocker and amlodipine is a calcium channel blocker, and the two are combined to lower blood pressure. A tablet with more telmisartan than labelled could, in principle, lower blood pressure more than intended, but the FDA classification suggests it does not expect significant harm. The agency has not published a risk assessment beyond the class. Those are the facts we can state without overstating them.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Hypertension Drugs Market report values the global market at USD 26.5 billion in 2023 and projects USD 38.3 billion by 2032, a CAGR of 4.2%. It says North America led with about USD 9.8 billion in 2023, Asia Pacific is the fastest-growing region at more than 5%, and hospital pharmacies held about 52% of the market. The page is inconsistent on its base year and forecast period, and was last updated in June 2024, so the figures are estimates. They describe the whole hypertension market and say nothing about this recall. See our Pharmaceutical section.
Timeline of the Mylan telmisartan amlodipine recall
- 1 October 2026: recall initiated.
- 16 October 2026: FDA classifies it as Class III.
- From about 19 October 2026: press coverage appears; the FDA notice is reported posted in the week of 21 October.
- 31 October and 30 November 2026: expiry dates of the affected lots.
General background: how generic drug quality is monitored
Generic drugmakers test each batch against specifications for strength, impurities and dissolution. Out-of-specification results can lead to recalls, even when the health risk is judged low. Class III recalls are common and generally reflect quality deviations rather than proven harm.
Our analysis of the Mylan telmisartan amlodipine recall
In our assessment, the Mylan telmisartan amlodipine recall is a quality-control event with a low assigned risk, and the coverage has probably made it sound more alarming than the FDA’s own classification does. The practical point for patients is simple: check the lot, speak to a pharmacist and do not stop treatment. By our own arithmetic, 21,620 bottles of 30 tablets is about 648,600 tablets, which gives a sense of scale but not of how many were taken.
What is not disclosed in the Mylan telmisartan amlodipine recall
- How far above specification the telmisartan content was.
- Any adverse events reported.
- The root cause and corrective action.
- A company statement or patient instruction.
Risks and caveats
We could not open the live enforcement record, so details come from press accounts that agree with each other. Class and status can change. This article is news reporting and not medical advice.
What to watch next
- Updates to the FDA enforcement record.
- Any company statement or customer letter.
- Whether further lots are added.
FAQ
Is this a new recall?
No. It was initiated on 1 October 2026; the coverage is renewed.
How serious is a Class III recall?
It is the lowest risk class, used where harm is not likely.
Should I stop taking telmisartan and amlodipine?
Do not stop without speaking to your doctor or pharmacist.
How we reported this: we relied on press accounts of the FDA enforcement record, the FDA’s recall pages and the Acumen Research and Consulting report cited above. Last updated 28 October 2026. This is news reporting and not advice.